Co-Diagnostics

Co-Diagnostics Buyback Yield

Buyback Yield of Co-Diagnostics (CODX) as of Nov 20, 2026.

Buyback Yield

0.00

Last updated:

Buyback Yield of Co-Diagnostics is 2025 0.00 . Buyback Yield of Co-Diagnostics was 2024 0.00 . It decreases by % lower compared to the previous year.

The Co-Diagnostics Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
0.54 USD
Jan 1, 2019
106.33 USD
Jan 1, 2020
355.61 USD
Jan 1, 2021
8.11 USD
Jan 1, 2022
255.99 USD
Jan 1, 2023
24.57 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
The Co-Diagnostics Buyback Yield history
YEARBuyback YieldYoY
0.00—
0.00-100.00%
24.57 %-90.40%
255.99 %+3,055.40%
8.11 %-97.72%
355.61 %+234.44%
106.33 %+19,577.46%
0.54 %-99.58%
127.37 %-0.00%
127.37 %+1,404.51%
8.47 %-59.31%
20.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

On Eulerpool you can find the complete historical development of Buyback Yield Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Co-Diagnostics

All Key Metrics — Co-Diagnostics